MX2016002502A - Composiciones farmaceuticas de bendamustina. - Google Patents

Composiciones farmaceuticas de bendamustina.

Info

Publication number
MX2016002502A
MX2016002502A MX2016002502A MX2016002502A MX2016002502A MX 2016002502 A MX2016002502 A MX 2016002502A MX 2016002502 A MX2016002502 A MX 2016002502A MX 2016002502 A MX2016002502 A MX 2016002502A MX 2016002502 A MX2016002502 A MX 2016002502A
Authority
MX
Mexico
Prior art keywords
bendamustine
pharmaceutical compositions
bendamustine pharmaceutical
pharmaceutical formulations
dry
Prior art date
Application number
MX2016002502A
Other languages
English (en)
Inventor
Voudouris Vasilios
Original Assignee
Voudouris Vasilios
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Voudouris Vasilios filed Critical Voudouris Vasilios
Publication of MX2016002502A publication Critical patent/MX2016002502A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Proporcionadas aquí son formulaciones farmacéuticas de bendamustina en polvo seco adecuadas para uso farmacéutico. También se proporcionan métodos para producir bendamustina en polvo seco. Las formulaciones farmacéuticas pueden utilizarse para cualquier enfermedad que es sensible al tratamiento con bendamustina, tal como enfermedades neoplásicas.
MX2016002502A 2013-08-27 2014-08-22 Composiciones farmaceuticas de bendamustina. MX2016002502A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361870609P 2013-08-27 2013-08-27
PCT/US2014/052341 WO2015031198A2 (en) 2013-08-27 2014-08-22 Bendamustine pharmaceutical compositions

Publications (1)

Publication Number Publication Date
MX2016002502A true MX2016002502A (es) 2017-02-28

Family

ID=52584085

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016002502A MX2016002502A (es) 2013-08-27 2014-08-22 Composiciones farmaceuticas de bendamustina.
MX2020006075A MX2020006075A (es) 2013-08-27 2016-02-25 Composiciones farmaceuticas de bendamustina.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020006075A MX2020006075A (es) 2013-08-27 2016-02-25 Composiciones farmaceuticas de bendamustina.

Country Status (11)

Country Link
US (6) US9849115B2 (es)
EP (1) EP3043648B1 (es)
JP (1) JP6571657B2 (es)
CN (2) CN109953954A (es)
AU (5) AU2014311570C1 (es)
CA (1) CA2922099C (es)
ES (1) ES2957541T3 (es)
IL (1) IL244133A0 (es)
MX (2) MX2016002502A (es)
WO (1) WO2015031198A2 (es)
ZA (1) ZA201601645B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9849115B2 (en) 2013-08-27 2017-12-26 Vasilios Voudouris Bendamustine pharmaceutical compositions
AU2015229842B2 (en) * 2014-03-13 2020-06-25 Vasilios VOUDOURIS Bendamustine solid dispersions and continuous infusion
JP6937016B2 (ja) * 2017-09-06 2021-09-22 東京理化器械株式会社 噴霧乾燥装置

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030203036A1 (en) * 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
WO1999033467A1 (en) * 1997-12-31 1999-07-08 Choongwae Pharma Corporation Method and composition of an oral preparation of itraconazole
SE0000773D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US20030105141A1 (en) 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
JP4644397B2 (ja) * 2001-09-05 2011-03-02 信越化学工業株式会社 難溶性薬物を含む医薬用固形製剤の製造方法
AU2002346472A1 (en) 2001-11-20 2003-06-10 Advanced Inhalation Research, Inc. Particulate compositions for improving solubility of poorly soluble agents
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN1887261A (zh) 2006-07-25 2007-01-03 济南帅华医药科技有限公司 含苯达莫司汀的复方抗癌缓释注射剂
CN1887269A (zh) * 2006-07-25 2007-01-03 济南帅华医药科技有限公司 一种含苯达莫司汀及其增效剂的抗癌缓释注射剂
DE102007009242A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
US20090130198A1 (en) 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
AR072777A1 (es) 2008-03-26 2010-09-22 Cephalon Inc Formas solidas de clorhidrato de bendamustina
CN102164579B (zh) * 2008-09-25 2014-10-15 赛福伦公司 苯达莫司汀的液体配制品
ES2451540T3 (es) 2008-12-03 2014-03-27 Astellas Deutschland Gmbh Formas de dosificación oral de bendamustina
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
RU2734236C2 (ru) * 2009-02-25 2020-10-13 Софткемо Фарма Корп. Композиции бендамустина и циклополисахарида
US20100273730A1 (en) 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
CA2760085A1 (en) * 2009-04-28 2010-11-04 Cephalon, Inc. Oral formulations of bendamustine
PT3158991T (pt) 2010-01-28 2021-06-23 Eagle Pharmaceuticals Inc Formulações de bendamustina
WO2011103150A2 (en) * 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
WO2012103226A2 (en) 2011-01-25 2012-08-02 Dr. Reddy's Laboratories Ltd. Bendamustine formulations
WO2013102920A1 (en) 2011-11-18 2013-07-11 Astron Research Limited Stable lyophilized formulation of bendamustine
EP2811984B1 (en) 2012-02-06 2015-08-26 Fresenius Kabi Oncology Limited Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
US20130210879A1 (en) 2012-02-14 2013-08-15 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
CA2867295C (en) 2012-03-20 2020-08-11 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
EP2641592A1 (en) 2012-03-23 2013-09-25 Salmon Pharma GmbH Pharmaceutical formulation comprising bendamustine
WO2014004707A1 (en) 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
US9849115B2 (en) 2013-08-27 2017-12-26 Vasilios Voudouris Bendamustine pharmaceutical compositions
AU2015229842B2 (en) 2014-03-13 2020-06-25 Vasilios VOUDOURIS Bendamustine solid dispersions and continuous infusion

Also Published As

Publication number Publication date
CN105491886A (zh) 2016-04-13
MX2020006075A (es) 2020-08-24
AU2014311570C1 (en) 2018-08-02
EP3043648C0 (en) 2023-09-20
US20210008036A1 (en) 2021-01-14
ZA201601645B (en) 2017-04-26
AU2020286280A1 (en) 2021-01-14
US9061011B1 (en) 2015-06-23
JP6571657B2 (ja) 2019-09-04
US20180071263A1 (en) 2018-03-15
CN105491886B (zh) 2019-01-29
CA2922099C (en) 2022-11-29
IL244133A0 (en) 2016-04-21
EP3043648A4 (en) 2017-11-22
JP2016531138A (ja) 2016-10-06
US20230310381A1 (en) 2023-10-05
CN109953954A (zh) 2019-07-02
EP3043648B1 (en) 2023-09-20
CA2922099A1 (en) 2015-03-05
US10786486B2 (en) 2020-09-29
AU2014311570B2 (en) 2018-04-19
EP3043648A2 (en) 2016-07-20
AU2014311570A1 (en) 2016-03-10
US11701344B2 (en) 2023-07-18
US9849115B2 (en) 2017-12-26
AU2018206777A1 (en) 2018-08-09
US20220079923A1 (en) 2022-03-17
AU2022263496A1 (en) 2022-12-08
WO2015031198A3 (en) 2015-04-23
ES2957541T3 (es) 2024-01-22
US20150065549A1 (en) 2015-03-05
AU2020286183A1 (en) 2021-01-07
WO2015031198A2 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
JOP20200192A1 (ar) أجسام مضادة لـ tigit
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
IN2015DN01156A (es)
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
MX2015010125A (es) Derivados de piridazinona-amidas.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
PH12015502161A1 (en) Therapeutic compounds and compositions
MX366317B (es) Composiciones y metodos para tratar la inflamacion cronica y las enfermedades inflamatorias.
EA201591712A1 (ru) Антибиотические композиции на основе цефтолозана
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.
PH12015502703A1 (en) Pharmaceutical compositions
PL3079684T3 (pl) Kompozycje i sposoby do leczenia chorób związanych z układem renina-angiotensyna
HK1198128A1 (en) Use of arctigenin in the preparation of medicament for the treatment of gastrointestinal ulcer diseases
IN2013MU03855A (es)
TH1401006421A (th) สารประกอบสำหรับการใช้ในการผลิตยาสำหรับการรักษาโรคผิวหนังที่ตอบสนองต่อสเตียรอยด์

Legal Events

Date Code Title Description
FG Grant or registration